Provectus Biopharmaceuticals, Inc. – OTC:PVCT

Provectus Biopharmaceuticals stock price today

$0.08
-0.04
-34.21%
Financial Health
0
1
2
3
4
5
6
7
8
9

Provectus Biopharmaceuticals stock price monthly change

+4.42%
month

Provectus Biopharmaceuticals stock price quarterly change

+4.42%
quarter

Provectus Biopharmaceuticals stock price yearly change

+22.12%
year

Provectus Biopharmaceuticals key metrics

Market Cap
50.34M
Enterprise value
67.09M
P/E
-15.48
EV/Sales
N/A
EV/EBITDA
-12.39
Price/Sales
N/A
Price/Book
-10.42
PEG ratio
-1.03
EPS
N/A
Revenue
590.75K
EBITDA
-2.42M
Income
-2.77M
Revenue Q/Q
16.11%
Revenue Y/Y
-41.30%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
-411.11%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Provectus Biopharmaceuticals stock price history

Provectus Biopharmaceuticals stock forecast

Provectus Biopharmaceuticals financial statements

Provectus Biopharmaceuticals, Inc. (OTC:PVCT): Profit margin
Jun 2023 161.84K -835.06K -515.97%
Sep 2023 69.73K -775.83K -1112.59%
Dec 2023 121.11K -663.41K -547.78%
Mar 2024 238.07K -504.04K -211.72%
Provectus Biopharmaceuticals, Inc. (OTC:PVCT): Debt to assets
Jun 2023 1686603 8.98M 532.64%
Sep 2023 1690093 9.20M 544.9%
Dec 2023 1448843 9.04M 624.1%
Mar 2024 1078991 8.52M 790.43%
Provectus Biopharmaceuticals, Inc. (OTC:PVCT): Cash Flow
Jun 2023 -617.78K 0 656.44K
Sep 2023 -768.87K -49.99K 817.85K
Dec 2023 -561.21K 49.99K 201.55K
Mar 2024 -1.04M 0 781.09K

Provectus Biopharmaceuticals alternative data

Provectus Biopharmaceuticals, Inc. (OTC:PVCT): Employee count
Aug 2023 4
Sep 2023 4
Oct 2023 4
Nov 2023 4
Dec 2023 4
Jan 2024 4
Feb 2024 4
Mar 2024 4
Apr 2024 4
May 2024 4
Jun 2024 4
Jul 2024 4

Provectus Biopharmaceuticals other data

0.05% -0.00%
of PVCT is owned by hedge funds
218.62K -7.65K
shares is hold by hedge funds

Provectus Biopharmaceuticals, Inc. (OTC:PVCT): Insider trades (number of shares)
Period Buy Sel
Nov 2024 80365 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
PERSHING EDWARD director, officer: CEO
Series D-1 Convertible Preferred Stock 18,880 N/A N/A
Option
PERSHING EDWARD director, officer: CEO
8% Unsecured Convertible Promissory Note 0 $2.86 $0
Purchase
PERSHING EDWARD director, officer: CEO
Series D-1 Convertible Preferred Stock 80,365 N/A N/A
Option
PERSHING EDWARD director, officer: CEO
Series D-1 Convertible Preferred Stock 28,320 N/A N/A
Option
PERSHING EDWARD director, officer: CEO
8% Unsecured Convertible Promissory Note 0 $2.86 $0
Option
PERSHING EDWARD director, officer: CEO
Series D-1 Convertible Preferred Stock 47,199 N/A N/A
Option
PERSHING EDWARD director, officer: CEO
8% Unsecured Convertible Promissory Note 0 $2.86 $0
Option
PERSHING EDWARD director, officer: CEO
Series D-1 Convertible Preferred Stock 47,180 N/A N/A
Option
PERSHING EDWARD director, officer: CEO
8% Unsecured Convertible Promissory Note 0 $2.86 $0
Option
PERSHING EDWARD director, officer: CEO
Series D-1 Convertible Preferred Stock 47,190 N/A N/A
  • What's the price of Provectus Biopharmaceuticals stock today?

    One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.08.

  • When is Provectus Biopharmaceuticals's next earnings date?

    Unfortunately, Provectus Biopharmaceuticals's (PVCT) next earnings date is currently unknown.

  • Does Provectus Biopharmaceuticals pay dividends?

    No, Provectus Biopharmaceuticals does not pay dividends.

  • How much money does Provectus Biopharmaceuticals make?

    Provectus Biopharmaceuticals has a market capitalization of 50.34M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 43.61% to 557.71K US dollars.

  • What is Provectus Biopharmaceuticals's stock symbol?

    Provectus Biopharmaceuticals, Inc. is traded on the OTC under the ticker symbol "PVCT".

  • What is Provectus Biopharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Provectus Biopharmaceuticals?

    Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Provectus Biopharmaceuticals have?

    As Jul 2024, Provectus Biopharmaceuticals employs 4 workers.

  • When Provectus Biopharmaceuticals went public?

    Provectus Biopharmaceuticals, Inc. is publicly traded company for more then 25 years since IPO on 7 Jun 2000.

  • What is Provectus Biopharmaceuticals's official website?

    The official website for Provectus Biopharmaceuticals is provectusbio.com.

  • Where are Provectus Biopharmaceuticals's headquarters?

    Provectus Biopharmaceuticals is headquartered at 10025 Investment Drive, Knoxville, TN.

  • How can i contact Provectus Biopharmaceuticals?

    Provectus Biopharmaceuticals's mailing address is 10025 Investment Drive, Knoxville, TN and company can be reached via phone at +86 65945999.

Provectus Biopharmaceuticals company profile:

Provectus Biopharmaceuticals, Inc.

provectusbio.com
Exchange:

OTC

Full time employees:

4

Industry:

Biotechnology

Sector:

Healthcare

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.

10025 Investment Drive
Knoxville, TN 37932

CIK: 0000315545
ISIN: US74373P1084
CUSIP: 74373P108